Usted buscó: ibandroonhappe (Estonio - Inglés)

ibandroonhappe
(%)

ibandroonhappe annus
ibandronic acid dose

ibandroonhappe süstelahus on praktiliselt naatriumivaba.
ibandronic acid injection is essentially sodium free.

ibandroonhappe imendumata fraktsioon elimineeritakse väljaheitega.
the unabsorbed fraction of ibandronic acid is eliminated unchanged in the faeces.

ibandroonhappe suukaudne annus 2, 5 mg päevas
(%)

ibandroonhappe 2,5 mg kord päevas manustatavad tabletid
ibandronic acid 2.5 mg daily tablets

iga 3 kuu järel manustatav ibandroonhappe 3 mg süstelahus
ibandronic acid 3 mg injection every 3 months

ibandroonhappe farmakodünaamiliseks toimeks on luukoe resorptsiooni pärssimine.
the pharmacodynamic action of ibandronic acid is inhibition of bone resorption.

genotoksilisuse test ei ole näidanud ibandroonhappe mõju geneetilistele omadustele.
tests for genotoxicity revealed no evidence of effects on genetic activity for ibandronic acid.

toiduga koos võtmisel ibandroonhappe suukaudne biosaadavus üldiselt väheneb.
oral bioavailability of ibandronic acid is generally reduced in the presence of food.

genotoksilisust hindav test ei ole näidanud ibandroonhappe mõju geneetilistele omadustele.
tests for genotoxicity revealed no evidence of genetic activity for ibandronic acid.

enne ravi alustamist ibandroonhappe süstelahusega, tuleb korrigeerida olemasolev hüpokaltseemia.
existing hypocalcaemia must be corrected before starting ibandronic acid injection therapy.

puuduvad andmed ibandroonhappe kasutamise kohta alla 18-aastastel patsientidel.
there are no data on the use of ibandronic acid in patients less than 18 years old.

ibandroonhappe üldkliirens on väike - keskmise väärtusega 84...160 ml/min.
total clearance of ibandronic acid is low with average values in the range 84-160 ml/min.

ibandroonhappe kogukliirens langes raske neerukahjustusega isikutel 44 ml/ min- le.
subjects with severe renal failure (clcr less than 30 ml/ min) receiving daily oral administration of 10 mg ibandronic acid for 21 days, had 2-3 fold higher plasma concentrations than subjects with normal renal function and total clearance of ibandronic acid was 44 ml/ min.

ibandroonhappe üldkliirens on väike – keskmise väärtusega vahemikus 84...160 ml/min.
total clearance of ibandronic acid is low with average values in the range 84-160 ml/min.

ibandroonhappe kasutamisel on kirjeldatud silmapõletiku (uveiidi, episkleriidi ja skleriidi) juhtusid.
ocular inflammation events such as uveitis, episcleritis and scleritis have been reported with ibandronic acid.

ibandroonhappe ekspositsioon erineva neerukahjustuse raskusastmega patsientidel on seotud kreatiniini kliirensiga (clcr).
exposure to ibandronic acid in patients with various degrees of renal impairment is related to creatinine clearance (clcr).